Clascoterone 5% topical solution, a novel anti-androgen that targets hair follicle androgen receptors without measurable systemic absorption, has demonstrated significant hair regrowth in men with androgenetic alopecia (AGA), according to topline data from two Phase III clinical trials.
The studies, conducted in the United States and Europe and involving 1,465 participants, showed that clascoterone 5% delivered robust, statistically significant improvements in Target-Area Hair Count (TAHC) compared with placebo. One trial reported a 539% relative improvement, while the second showed a 168% improvement. These results highlight strong efficacy without the systemic risks associated with oral therapies.
Safety and tolerability were comparable to placebo, with treatment-emergent adverse events (TEAEs) largely unrelated to the drug. Patient-reported outcomes (PROs) further confirmed meaningful improvements in hair growth, with one study reaching statistical significance and the combined analysis across both trials fully consistent with objective hair count measures.
“This represents a major milestone for patients with male pattern hair loss,” said Dr. Maria Hordinsky, MD, R.W. Goltz Professor of Dermatology at the University of Minnesota. “For decades, patients have had to choose between treatments with limited efficacy or systemic safety concerns. Clascoterone 5% topical solution delivers real, measurable results with negligible systemic exposure, potentially redefining how dermatologists treat AGA worldwide.”
Giovanni Di Napoli, CEO of Cosmo, added: “Androgenetic alopecia is more than a cosmetic issue—it affects confidence, identity, and emotional well-being. For the first time in over 30 years, we have a new mechanism that could truly change that reality. With strong efficacy and a favorable safety profile, clascoterone 5% opens the door to a fundamentally better treatment paradigm for patients.”
Cosmo plans to complete the required 12-month safety follow-up in spring 2026. Upon completion, the company intends to submit parallel regulatory applications to the FDA and EMA, positioning clascoterone 5% as the first topical androgen receptor inhibitor approved for AGA.
Key Trial Highlights
- Indication: Male androgenetic alopecia
- Patients: 1,465 across two Phase III studies, the largest for topical AGA treatment
- Efficacy: 5.39x (539%) and 1.68x (168%) relative improvements vs. vehicle
- Patient-Reported Outcomes (PROs): Statistically significant when studies combined
- Safety: TEAEs comparable to placebo
- Mechanism: First topical androgen receptor inhibitor targeting the root cause of AGA
- Patent Protection: Valid through 2036
- Market Potential: Over $20B U.S. opportunity, confirmed by Cosmo research
- Next Milestone: Regulatory submissions following 12-month safety completion
Clascoterone leverages the same active ingredient used in Winlevi, Cosmo’s FDA- and EMA-approved topical acne treatment, which has a well-established dermatologic safety profile and over 1.6 million prescriptions written in the U.S. since launch.
